![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase I/II Study of High-Dose Acetaminophen With Carmustine in Patients With Metastatic Melanoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase II | Treatment | Closed | Over 18 | MSKCC-97124 NCI-H98-0014, NCT00003346 |
Objectives - Determine the maximum tolerated dose (MTD) and the optimal biologic dose (OBD) of high-dose acetaminophen when given alone, and the MTD of carmustine when given with acetaminophen at the OBD in patients with metastatic melanoma (Phase I closed to accrual 3/7/2001).
- Determine the dose of acetaminophen that results in maximal depletion of intracellular glutathione in these patients.
- Assess the antitumor activity of high-dose acetaminophen in these patients.
- Assess the toxicity and antitumor activity of carmustine when administered with high-dose acetaminophen in these patients.
Entry Criteria Disease Characteristics:
- Histologically confirmed stage IV melanoma or stage III melanoma not
potentially curable by surgery
- Phase I: (closed to accrual 3/7/2001) measurable or evaluable disease
required
- Phase II: At least 2 measurable subcutaneous or cutaneous metastases
that are
accessible for biopsy
Prior/Concurrent Therapy:
Biologic therapy: - At least 4 weeks since prior immunotherapy
Chemotherapy: - At least 4 weeks since prior chemotherapy (6 weeks for
mitomycin)
- No prior nitrosoureas
- No prior hepatic perfusions with chemotherapy
Endocrine therapy: - No concurrent oral contraceptives
Radiotherapy: - At least 4 weeks since prior radiotherapy
Surgery: Other: - No concurrent vitamin, mineral, or garlic
supplements
- At least 7 days since prior garlic or alcohol
- No concurrent treatment with medications known to affect P450
hepatic enzymes
- No concurrent treatment with calcium channel
blockers
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - WBC at least 4,000/mm3
- Hemoglobin at least 9 g/dL
- Platelet count at least 100,000/mm3
- No active bleeding
Hepatic: - AST less than 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase less than 1.5 times ULN
- PT/PTT within normal range
Renal: Pulmonary: - No interstitial lung disease or unexplained interstitial
infiltrates on chest x-ray
- No chronic obstructive pulmonary disease
- No asthma requiring treatment
Other: - No active infection requiring antimicrobial drugs
- Not pregnant or nursing
- Fertile patients must use effective barrier contraception
- No allergies to acetaminophen or acetylcysteine
Expected Enrollment 80A total of 30-80 patients will be accrued for this study within 40 months. Outline This is a dose-escalation study. - Phase I: (closed to accrual 3/7/2001) Patients receive a single oral
dose of acetaminophen, then acetylcysteine IV over 20 hours, beginning 6-8
hours after the acetaminophen. This treatment is repeated 3 weeks later. On
day 1 of the first treatment, patients also receive carmustine IV over 1 hour,
before the acetylcysteine. Courses repeat every 6 weeks in the absence of
disease progression or unacceptable toxicity.
Cohorts of 3-6 patients each receive escalating doses of acetaminophen
to determine the optimal biological dose (OBD). The OBD is defined as the
lowest dose at or preceding the maximum tolerated dose (MTD) that results in
maximal depletion of glutathione. The MTD is defined as the dose at which no
more than 1 to 6 patients experience dose-limiting toxicity (DLT). Once the OBD is established for acetaminophen, cohorts of 3-6 patients
each receive escalating doses of carmustine. The MTD is defined as for
acetaminophen. Dose escalation does not proceed until all patients are
observed for 6 weeks after receiving carmustine. Once the OBD for acetaminophen and MTD for carmustine are determined, 3
more patients are treated at 3 week intervals instead of 6 weeks. If no DLT
is observed, this is the dose and schedule for the phase II portion of the
study.
- Phase II: A cohort of 14 patients receives oral acetaminophen and
acetylcysteine IV every 3 weeks. Another cohort of 14 patients receives oral
acetaminophen and acetylcysteine IV, then oral acetaminophen, carmustine IV,
and acetylcysteine IV 3 weeks later. Patients continue therapy in the absence
of disease progression or unacceptable toxicity.
Trial Contact Information
Trial Lead Organizations Memorial Sloan-Kettering Cancer Center ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | Paul Chapman, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | Ph: 646-888-2378; 800-525-2225 |
| ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | Phase I-II Trial of High-Dose Acetaminophen With Carmustine in Patients With metastatic Melanoma | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 1997-11-24 | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00003346 | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 1998-05-22 | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2002-12-03 | ![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) | NCI Grant/Contract Number | | CA08748 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](https://webarchive.library.unt.edu/eot2008/20090511123115im_/http://www.cancer.gov/images/spacer.gif) |